Original Article
Timing and Magnitude of Increases in Levothyroxine Requirements during Pregnancy in Women with Hypothyroidism
N Engl J Med 2004; 351:241-249July 15, 2004
- Abstract
Background
Hypothyroidism during pregnancy has been associated with impaired cognitive development and increased fetal mortality. During pregnancy, maternal thyroid hormone requirements increase. Although it is known that women with hypothyroidism should increase their levothyroxine dose during pregnancy, biochemical hypothyroidism occurs in many. In this prospective study we attempted to identify precisely the timing and amount of levothyroxine adjustment required during pregnancy.
Methods
Women with hypothyroidism who were planning pregnancy were observed prospectively before and throughout their pregnancies. Thyroid function, human chorionic gonadotropin, and estradiol were measured before conception, approximately every two weeks during the first trimester, and monthly thereafter. The dose of levothyroxine was increased to maintain the thyrotropin concentration at preconception values throughout pregnancy.
Results
Twenty pregnancies occurred in 19 women and resulted in 17 full-term births. An increase in the levothyroxine dose was necessary during 17 pregnancies. The mean levothyroxine requirement increased 47 percent during the first half of pregnancy (median onset of increase, eight weeks of gestation) and plateaued by week 16. This increased dose was required until delivery.
Conclusions
Levothyroxine requirements increase as early as the fifth week of gestation. Given the importance of maternal euthyroidism for normal fetal cognitive development, we propose that women with hypothyroidism increase their levothyroxine dose by approximately 30 percent as soon as pregnancy is confirmed. Thereafter, serum thyrotropin levels should be monitored and the levothyroxine dose adjusted accordingly.
Media in This Article
Figure 1
Changes in Maternal Hormone Concentrations and the Levothyroxine Dose during Gestation.Figure 2
Gestational Week of the Initial Increase in the Levothyroxine Dose.Article Activity
- Article
Primary hypothyroidism is common, occurring in 3 to 10 percent of women, frequently with its onset during the childbearing years.1,2 An estimated 1 to 2 percent of all pregnant women receive levothyroxine therapy for hypothyroidism. Epidemiologic studies indicate that 0.4 percent of pregnant women have serum thyrotropin concentrations above 10 μU per milliliter at 15 to 18 weeks of gestation.3,4 Thus, in the United States alone, a minimum of 12,000 to 16,000 infants are born each year to women with either inadequately treated or undiscovered primary hypothyroidism.5,6
During pregnancy, women's thyroid physiology undergoes well-defined changes, including an approximate doubling in thyroxine-binding globulin concentrations due to increases in estradiol concentrations, as well as a 30 to 40 percent increase in plasma volume.7-11 These changes result in a significant increase in the total thyroxine pool, primarily during the first trimester. This increment may be provided largely by thyroid stimulation induced by human chorionic gonadotropin,7,8,10 since a slight increase in free thyroxine and a reduction in thyrotropin occur at 9 to 12 weeks of gestation.8,12 In general, however, the thyrotropin concentration stays within the normal range for the remainder of pregnancy, despite the estimated 30 to 50 percent increase in the levothyroxine requirement.9,10,13-15
Although this process is now recognized by endocrinologists and some hypothyroid patients are alerted to the need for such an increase, many pregnant women are found to have a high serum thyrotropin concentration at the time of their initial obstetrical examination, at 8 to 12 weeks of gestation.3,4,10,13,16-22 Thus, current practice permits a transient period of maternal hypothyroxinemia in the first trimester, which is a time when the free thyroxine concentration is typically slightly increased. It is known that the pregnant woman is the sole source of the fetal supply of thyroid hormones from conception to approximately 13 weeks of gestation when fetal thyroid function has developed. Given the possible association between gestational hypothyroidism and impaired intellectual and cognitive development in offspring, as well as the increased rate of fetal death in women with an elevated thyrotropin concentration,3,20,23,24 the current approach is suboptimal.
In this prospective study, we sought to delineate the precise timing and pattern of the increased thyroid hormone requirement during pregnancy in order to determine appropriate recommendations for preventing first-trimester hypothyroidism. We used a strategy involving frequent monitoring of serum thyrotropin concentrations with concomitant adjustments in the dose of levothyroxine to maintain thyrotropin at preconception concentrations.
Methods
Women with primary hypothyroidism who desired pregnancy were recruited from the endocrine outpatient clinics at Brigham and Women's Hospital, Boston (Table 1Table 1
Descriptive Characteristics of 19 Women Followed Prospectively during Pregnancy.). Maternal thyroid function, estradiol, and human chorionic gonadotropin were measured before and during pregnancy. Our goal was to assess biochemical thyroid status after the first missed menstrual cycle, every two weeks throughout the first trimester, and monthly thereafter until the completion of the pregnancy. This aim was achieved in most, but not all, subjects.At each visit, two aliquots of serum were obtained. The first was frozen and saved for batch analysis at the completion of the study. The second was analyzed immediately to determine the thyrotropin concentration (normal range, 0.5 to 5.0 μU per milliliter) and free thyroxine index. The dose of levothyroxine was adjusted as needed, usually in 25-μg increments, to maintain the thyrotropin concentration at preconception values.
Six of the subjects had a history of thyroid cancer; in these subjects, the levothyroxine dose was adjusted when the thyrotropin concentration was greater than 0.5 μU per milliliter. For all the others, the levothyroxine dose was adjusted if the thyrotropin concentration was greater than 5.0 μU per milliliter. Specifically, the levothyroxine dose was increased by 25 μg in all the subjects whenever initial blood testing revealed thyrotropin concentrations above the target range. Thereafter, the dose of levothyroxine was increased by 12.5 μg if subsequent thyrotropin values were between 5 and 10 μU per milliliter (or 0.5 to 5.0 μU per milliliter, in subjects with a history of thyroid cancer) and by 25 μg if subsequent thyrotropin values were greater than 10 μU per milliliter (or greater than 5.0 μU per milliliter, in subjects with a history of thyroid cancer). After delivery, levothyroxine was given in the doses used before conception. All the subjects returned for a repeated set of thyroid-function tests six weeks after delivery.
The subjects were instructed not to ingest any vitamins or products containing calcium, iron, or soy within four hours before or after the time they ingested their levothyroxine. The date of conception was estimated to be 2 weeks after the last menstrual period, and the gestational age was confirmed by fetal ultrasound examination at 16 weeks.
Analytic measurements of thyrotropin, thyroxine, triiodothyronine, free thyroxine, and human chorionic gonadotropin were performed with the use of a Bayer Advia Centaur analyzer. The thyroid hormone–binding ratio was determined by means of a normalized, two-step, competitive immunoassay version of a triiodothyronine-uptake assay.25 The result was normalized to serum samples containing normal concentrations of thyroxine and thyroxine-binding globulin. The free thyroxine index is the product of the thyroid hormone–binding ratio and the total thyroxine value, with a normal range of 5.0 to 11.0. Similarly, the free triiodothyronine index is the product of the thyroid hormone–binding ratio and the total triiodothyronine value, with a normal range of 70 to 170. The free-thyroxine assay is a direct competitive immunoassay in which the subject's thyroxine competes with a tagged thyroxine analogue for a limited amount of polyclonal rabbit anti-thyroxine antibody. At the time of batch analysis, specimens were thawed, mixed, and analyzed within two hours. Specimens were not diluted except for those with human chorionic gonadotropin values above 1000 U per liter, which were automatically diluted to 1:200.
Permission to perform this investigation was granted by the Brigham and Women's Hospital institutional review board. All the participants gave their written informed consent.
Statistical Analysis
Descriptive statistical data were compared with use of the Wilcoxon rank-sum test (for continuous data) or the chi-square test (for categorical data) and are presented according to subject or pregnancy, as appropriate. Changes in the results of thyroid-function tests, human chorionic gonadotropin and estradiol concentrations, and levothyroxine doses throughout pregnancy were graphed with the use of locally weighted polynomial regression to achieve the best-fit curve throughout pregnancy, with no attempt to document statistical significance. To assess the statistical significance of changes in various response variables during pregnancy, the results before pregnancy and at 10, 20, 30, and 38 weeks of gestation were analyzed by repeated-measures analysis of variance and by post hoc subgroup comparisons with use of the Newman–Keuls test. All data were analyzed with the use of SPSS software, version 11.0. P values of less than 0.05 were considered to indicate statistical significance.
Results
Nineteen women became pregnant; one became pregnant twice, and three became pregnant by assisted reproductive techniques. Overall, there were 20 pregnancies and 17 term deliveries (Table 1). The serum thyrotropin level increased during the first 10 weeks of gestation, prompting an increase in the levothyroxine dose in 85 percent of the group, including all the athyreotic subjects (Figure 1Figure 1
Changes in Maternal Hormone Concentrations and the Levothyroxine Dose during Gestation. and Table 2Table 2
Serum Values before and during Gestation in All Women Who Required an Increase in the Dose of Levothyroxine during Gestation.). An increase in the total thyroxine and triiodothyronine concentrations compensated for the decrease in the free hormone fraction, as reflected in the decreased thyroid hormone–binding ratio. The prescribed increments in levothyroxine (mean, 29 percent at 10 weeks), however, did not reproduce the typical increase in the free thyroxine index (and decrease in thyrotropin) that normally occur at the approximate time of the human chorionic gonadotropin peak. Both the free thyroxine index and the concentration of free thyroxine were constant throughout pregnancy (P=0.33) (Figure 1 and Table 2).7-9 In subjects without a history of thyroid cancer who required an increase in the dose of levothyroxine during pregnancy, the mean (±SD) thyrotropin concentration before pregnancy was 1.5±1.1 μU per milliliter, and at 38 weeks of gestation it was 1.4±0.3 μU per milliliter (P=0.92). In subjects with a history of thyroid cancer, the mean thyrotropin concentration before pregnancy was 0.05±0.04 μU per milliliter, and at 38 weeks of gestation it was 0.06±0.04 μU per milliliter (P=0.99). One woman required a decrease of 12.5 μg in the levothyroxine dose at 26 weeks to maintain goal thyrotropin concentrations thereafter.
The best-fit curve for the levothyroxine dose shows a rapid increase between 6 and 16 weeks of gestation and a subsequent plateau (Figure 1). At 10 weeks of gestation, the levothyroxine dose had increased by 29±25 percent as compared with the dose at baseline (P<0.001). At 20 weeks, the increase relative to baseline was 48 percent (P<0.001), but the dose remained stable thereafter (Table 2). The changes during the first half of pregnancy were chronologically associated with a rapid decrease in the thyroid hormone–binding ratio, reflecting the estradiol-induced increase in serum concentrations of thyroxine-binding globulin. Notably, the thyroid hormone–binding ratio decreased most rapidly when the levothyroxine requirement increased most rapidly. Both remained nearly unchanged between 20 and 38 weeks. However, estradiol concentrations increased exponentially throughout pregnancy (Figure 1 and Table 2).
The time at which an increased thyrotropin concentration was first observed varied between 4.4 and 16.0 weeks of gestation (median, 8 weeks) (Figure 2Figure 2
Gestational Week of the Initial Increase in the Levothyroxine Dose.). This observation was similar in subjects with a history of thyroid cancer and those without such a history. Nine of 17 subjects (53 percent) had a thyrotropin increment of greater than 1 μU per milliliter at the time of their first visit (mean, five weeks of gestation). The three subjects who became pregnant by means of assisted reproductive techniques appeared to have a greater increase in thyrotropin early during gestation than those with spontaneous pregnancies (Figure 3AFigure 3
Evidence Implicating Changes in Estradiol as a Key Contributor to Increased Levothyroxine Requirements during Early Pregnancy.). Serum estradiol concentrations at seven weeks of gestation were significantly higher in subjects who had become pregnant by assisted reproduction (1506±460 pg per milliliter [5527±1688 pmol per liter]) than the concentrations in the subjects who became pregnant spontaneously (484±265 pg per milliliter [1776±973 pmol per liter], P<0.01).That estradiol plays an important role in the increase in the levothyroxine requirement during pregnancy was also implied by the data from Subject 5, who conceived twice during the study. Her first pregnancy ended in spontaneous abortion at 14 weeks, and her second was a full-term pregnancy. Her levothyroxine requirements, in conjunction with her serum estradiol concentrations, increased at a similar time point and to a greater extent during her second pregnancy (Figure 3B).
Within two weeks after delivery, all the subjects resumed taking their prepregnancy dose of levothyroxine. Fourteen subjects returned for testing six to eight weeks after delivery. Thyrotropin concentrations had returned to prepregnancy values in all of them.
Discussion
This prospective study indicates that frequent testing in association with frequent adjustments in the dose of levothyroxine can be used to estimate when levothyroxine requirements increase during pregnancy, and by how much. Levothyroxine requirements increased in 85 percent of the cohort. In these subjects, a mean increase of 47 percent was necessary to maintain the thyrotropin concentration at a prepregnancy value. The required levothyroxine dose increased during the first 16 to 20 weeks of gestation but plateaued thereafter.
In normal pregnancy, there is a physiologic increase in free thyroxine and a decrease in thyrotropin, and these changes are maximal at the time the human chorionic gonadotropin concentration peaks (approximately 10 to 12 weeks of gestation).7-9,12 In our subjects, we did not observe this increase. Rather, there was a peak in the thyrotropin concentration at about 8 to 10 weeks of gestation, accompanied by a downward trend in the free thyroxine index. These results suggest that an important role of the human chorionic gonadotropin–thyroid axis in healthy women is to increase the thyroid hormone pool during the first trimester.
We did not directly quantitate the changes in thyroxine-binding globulin, since this variable has already been thoroughly studied.8 A rapid increase in unoccupied binding sites on this molecule can be inferred from the decrease in the thyroid hormone–binding ratio (a surrogate for the free fraction of triiodothyronine or thyroxine) during the first 20 weeks of gestation. The cause of the increase in thyroxine-binding globulin appears to be twofold: clearance decreased because of estradiol-altered hepatic glycosylation of thyroxine-binding globulin26 and an estradiol-induced increase in synthesis.14 During the second half of pregnancy, while serum estradiol continues to increase, there are only small increases in thyroxine-binding globulin8 and small decreases in the thyroid hormone–binding ratio. While other changes that could increase levothyroxine requirements occur early in pregnancy, the fact that estradiol causes sustained increases in thyrotropin concentrations, levothyroxine requirements, or both in hypothyroid women after menopause indicates that an elevated estradiol concentration per se is sufficient to cause this change.27
The possibility that increases in estradiol levels constitute a key etiologic factor in the need to increase the levothyroxine dose is also supported by our observation that subjects who had undergone assisted reproduction had earlier and relatively greater increases in serum levels of thyrotropin and estradiol than those who had conceived spontaneously. In addition, the increased levothyroxine requirement was noted during a successful, full-term pregnancy in one woman in whom a blunted increase in estradiol and levothyroxine requirements had been observed during a first, unsuccessful pregnancy. Furthermore, a slight increase in thyrotropin and a reduction in free thyroxine have been documented during assisted reproduction, even in women who have an intact thyroid.28 Thus, it is clear that assisted reproduction, probably because it involves a rapid increase in plasma estradiol concentrations, places a severe strain on the hypothalamic–pituitary–thyroid axis.
This analysis suggests that during the first half of pregnancy, thyroxine production (or levothyroxine intake) must exceed its metabolic clearance until the pool of thyroxine is large enough to allow normalization of free thyroxine and triiodothyronine, despite a high concentration of thyroxine-binding globulin. This phenomenon, first described more than a decade ago,10,13 may be due to a number of factors.
Increases in thyroxine-binding globulin are a possible contributor early in pregnancy, but the concentration of this protein plateaus by 20 weeks, as reflected in the stable thyroid hormone–binding ratio. Thus, this factor cannot explain the persistent increase in the levothyroxine requirement. A recent report of a similar fractional increase in the levothyroxine dose during pregnancy in a woman with partial deficiency in thyroxine-binding globulin supports this contention.22 Furthermore, a high concentration of thyroxine-binding globulin alone does not reduce the availability of thyroxine or triiodothyronine, since the free thyroxine and thyrotropin concentrations are normal throughout the second half of pregnancy.9
Additional factors, some of which may also be present during the first half of pregnancy, may contribute to the increased requirement. They include increased inactivation of triiodothyronine and thyroxine by type 3 iodothyronine deiodinase, which is widespread in the human fetoplacental unit and uterus, increases throughout pregnancy, and, at least in rats, may be augmented by estradiol.29,30 Maternal thyroxine and triiodothyronine are transferred to a congenitally hypothyroid fetus, but it is thought that this process does not take place when fetal thyroid function is normal.31 In addition, there is a continuous increase in maternal plasma volume that lasts into the third trimester, but the pattern of changes correlates poorly with the observed increases in the required dose of levothyroxine.11 Finally, thyroxine absorption, enterohepatic circulation, or other metabolic pathways may be modified in pregnant women, or factors such as redistribution of cardiac output could affect this process. Although these possibilities seem unlikely, especially in early pregnancy, they could be more important during the second half of pregnancy.
Whatever factors are responsible, however, it is clear that the requirement for thyroid hormone increases very early in pregnancy, typically before the first obstetrical visit. There is wide variability regarding the timing of initial and subsequent prenatal visits, and some authorities even advocate fewer such visits.32 If one assumes an initial visit at 10 weeks of gestation (12 weeks after the last menstrual period), 70 percent of our cohort would have been biochemically hypothyroid when first examined. Furthermore, the thyrotropin concentration would have increased in nearly all the women, especially those pregnant by assisted reproductive techniques.
The results of our study suggest that the prevention of hypothyroidism and its possible adverse effects on the fetus and pregnancy in this population requires the combined efforts of primary care physicians, endocrinologists, obstetricians, and the women themselves. On the basis of our observations, we propose a practical solution: women who are currently being treated for hypothyroidism should be given written instructions to increase their current dose of levothyroxine by taking two extra daily doses during each week (i.e., to increase the dose by 29 percent) beginning the week pregnancy is confirmed and to continue doing so until they are able to undergo thyroid-function testing and obtain appropriate professional guidance. On the basis of our data and those of others, it appears that during pregnancy about 85 percent of women with thyroid dysfunction will require a substantial increase in their usual dose of levothyroxine.13 For the 15 percent who do not, a moderate increment would merely suppress endogenous thyroxine production and not lead to thyrotoxicosis. We also suggest that written recommendations be given to all hypothyroid women to request a serum thyrotropin test from health care providers when pregnancy is confirmed. Although this approach may not completely satisfy the increased requirements of athyreotic women, existing data suggest that even partial treatment of gestational hypothyroidism may ameliorate developmental abnormalities.4,24
Thus, levothyroxine requirements increase early during pregnancy in most women with primary hypothyroidism, reaching a plateau after 16 to 20 weeks of gestation at a value about 47 percent higher than the prepregnancy value and persisting throughout pregnancy. Since an increase in the levothyroxine dose was required at a median of eight weeks of gestation and an additional five weeks is required for equilibration of any such change, we suggest that women with hypothyroidism be instructed to increase their usual levothyroxine intake by two additional doses each week immediately on confirmation of pregnancy and to contact their health care provider so that a program of test-guided dose adjustments can be instituted.
Presented in part at the annual meeting of the American Thyroid Association, Palm Beach, Fla., September 20, 2003.
Supported by training grants (DK-07529, HL-07609, and DK-44128) from the National Institutes of Health and by a research grant from the Endocrine Fellows Foundation.
Dr. Larsen reports having served as a consultant for Genzyme and Laboratory Inisiba.
Source Information
From the Thyroid Section, Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine (E.K.A., E.M., P.R.L.), and the Division of Clinical Laboratories, Department of Pathology (P.J., G.A.F.), Brigham and Women's Hospital and Harvard Medical School, Boston; and Valdosta Specialty Clinic, Valdosta, Ga. (J.L.).
Address reprint requests to Dr. Alexander at the Thyroid Section, Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., 2nd Fl., Boston, MA 02115, or at ekalexander@partners.org.
- References
References
1
Canaris GJ ,Manowitz NR ,Mayor G ,Ridgway EC . The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534
CrossRef | Web of Science | Medline2
Vanderpump MP ,Tunbridge WM ,French JM , et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43:55-68
CrossRef | Web of Science | Medline3
Allan WC ,Haddow JE ,Palomaki GE , et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen 2000;7:127-130
CrossRef | Web of Science | Medline4
Klein RZ ,Sargent JD ,Larsen PR ,Waisbren SE ,Haddow JE ,Mitchell ML . Relation of severity of maternal hypothyroidism to cognitive development of offspring. J Med Screen 2001;8:18-20
CrossRef | Web of Science | Medline5
Ventura SJ, Martin JA, Curtin SC, Mathews TJ, Park MM. Births: final data for 1998. National vital statistics reports. Vol. 48. No. 3. Hyattsville, Md.: National Center for Health Statistics, March 2000. (DHHS publication no. (PHS) 2000-1120 0-0215.)
6
Ventura SJ, Martin JA, Curtin SC, Menacker F, Hamilton BE. Births: final data for 1999. National vital statistics reports. Vol. 49. No. 1. Hyattsville, Md.: National Center for Health Statistics, March 2001. (DHHS publication no. (PHS) 2001-1120 1-0355.)
7
Burrow GN ,Fisher DA ,Larsen PR . Maternal and fetal thyroid function. N Engl J Med 1994;331:1072-1078
Full Text | Web of Science | Medline8
Glinoer D ,de Nayer P ,Bourdoux P , et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990;71:276-287
CrossRef | Web of Science | Medline9
Glinoer D . The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997;18:404-433
CrossRef | Web of Science | Medline10
Mandel SJ ,Larsen PR ,Seely EW ,Brent GA . Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 1990;323:91-96
Full Text | Web of Science | Medline11
Peck TM ,Arias F . Hematologic changes associated with pregnancy. Clin Obstet Gynecol 1979;22:785-798
CrossRef | Medline12
Harada A ,Hershman JM ,Reed AW , et al. Comparison of thyroid stimulators and thyroid hormone concentrations in the sera of pregnant women. J Clin Endocrinol Metab 1979;48:793-797
CrossRef | Web of Science | Medline13
Kaplan MM . Monitoring thyroxine treatment during pregnancy. Thyroid 1992;2:147-152
CrossRef | Web of Science | Medline14
Glinoer D ,Gershengorn MC ,Dubois A ,Robbins J . Stimulation of thyroxine-binding globulin synthesis by isolated rhesus monkey hepatocytes after in vivo beta-estradiol administration. Endocrinology 1977;100:807-813
CrossRef | Web of Science | Medline15
Roti E ,Fang SL ,Green K ,Emerson CH ,Braverman LE . Human placenta is an active site of thyroxine and 3,3'5-triiodothyronine tyrosyl ring deiodination. J Clin Endocrinol Metab 1981;53:498-501
CrossRef | Web of Science | Medline16
Pekonen F ,Teramo K ,Ikonen E ,Osterlund K ,Makinen T ,Lamberg BA . Women on thyroid hormone therapy: pregnancy course, fetal outcome, and amniotic fluid thyroid hormone level. Obstet Gynecol 1984;63:635-638
Web of Science | Medline17
Girling JC ,de Swiet M . Thyroxine dosage during pregnancy in women with primary hypothyroidism. Br J Obstet Gynaecol 1992;99:368-370
CrossRef | Medline18
McDougall IR ,Maclin N . Hypothyroid women need more thyroxine when pregnant. J Fam Pract 1995;41:238-240
Web of Science | Medline19
Caixas A ,Albareda M ,Garcia-Patterson A ,Rodriguez-Espinosa J ,de Leiva A ,Corcoy R . Postpartum thyroiditis in women with hypothyroidism antedating pregnancy? J Clin Endocrinol Metab 1999;84:4000-4005
CrossRef | Web of Science | Medline20
Abalovich M ,Gutierrez S ,Alcaraz G ,Maccallini G ,Garcia A ,Levalle O . Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002;12:63-68
CrossRef | Web of Science | Medline21
Chopra IJ ,Baber K . Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine dose requirement in pregnancy? Metabolism 2003;52:122-128
CrossRef | Web of Science | Medline22
Zigman JM ,Cohen SE ,Garber JR . Impact of thyroxine-binding globulin on thyroid hormone economy during pregnancy. Thyroid 2003;13:1169-1175
CrossRef | Web of Science | Medline23
Delange F . The disorders induced by iodine deficiency. Thyroid 1994;4:107-128
CrossRef | Web of Science | Medline24
Haddow JE ,Palomaki GE ,Allan WC , et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999;341:549-555
Full Text | Web of Science | Medline25
Larsen PR ,Alexander NM ,Chopra IJ , et al. Revised nomenclature for tests of thyroid hormones and thyroid-related proteins in serum. J Clin Endocrinol Metab 1987;64:1089-1094
CrossRef | Web of Science | Medline26
Ain KB ,Mori Y ,Refetoff S . Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 1987;65:689-696
CrossRef | Web of Science | Medline27
Arafah BM . Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001;344:1743-1749
Full Text | Web of Science | Medline28
Muller AF ,Verhoeff A ,Mantel MJ ,De Jong FH ,Berghout A . Decrease of free thyroxine levels after controlled ovarian hyperstimulation. J Clin Endocrinol Metab 2000;85:545-548
CrossRef | Web of Science | Medline29
Huang SA ,Dorfman DM ,Genest DR ,Salvatore D ,Larsen PR . Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium. J Clin Endocrinol Metab 2003;88:1384-1388
CrossRef | Web of Science | Medline30
Wasco EC ,Martinez E ,Grant KS ,St Germain EA ,St Germain DL ,Galton VA . Determinants of iodothyronine deiodinase activities in rodent uterus. Endocrinology 2003;144:4253-4261
CrossRef | Web of Science | Medline31
Vulsma T ,Gons MH ,de Vijlder JJM . Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 1989;321:13-16
Full Text | Web of Science | Medline32
McDuffie RS Jr ,Beck A ,Bischoff K ,Cross J ,Orleans M . Effect of frequency of prenatal care visits on perinatal outcome among low-risk women: a randomized controlled trial. JAMA 1996;275:847-851
CrossRef | Web of Science | Medline
- Citing Articles (105)
Citing Articles
1
Brian Casey. 2012. Hypothyroidism and Hyperthyroidism. , 178-182.
CrossRef2
Deepak Khandelwal, Nikhil Tandon. (2012) Overt and Subclinical Hypothyroidism. Drugs 72:1, 17-33
CrossRef3
Gilad Twig, Avi Shina, Howard Amital, Yehuda Shoenfeld. (2012) Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. Journal of Autoimmunity
CrossRef4
Clarisa R. Gracia, Christopher B. Morse, Grace Chan, Samantha Schilling, Maureen Prewitt, Mary D. Sammel, Susan J. Mandel. (2012) Thyroid function during controlled ovarian hyperstimulation as part of in vitro fertilization. Fertility and Sterility
CrossRef5
Blaz Krhin, Nikola Besic. (2012) Effectiveness of L-thyroxine treatment on TSH suppression during pregnancy in patients with a history of thyroid carcinoma after total thyroidectomy and radioiodine ablation. Radiology and Oncology 1:-1, 1-6
CrossRef6
Dorota A. Krajewski, Kenneth D. Burman. (2011) Thyroid Disorders in Pregnancy. Endocrinology & Metabolism Clinics of North America 40:4, 739-763
CrossRef7
A. Lansdown, D.A. Rees. (2011) Endocrine oncology in pregnancy. Best Practice & Research Clinical Endocrinology & Metabolism 25:6, 911-926
CrossRef8
Roberto Negro, Jorge Hector Mestman. (2011) Thyroid disease in pregnancy. Best Practice & Research Clinical Endocrinology & Metabolism 25:6, 927-943
CrossRef9
Steven R Bayer. 2011. Preconceptional counseling. , 35-50.
CrossRef10
Philippe Caron. (2011) Dysthyroïdies et grossesse. La Presse Médicale
CrossRef11
B. Vaidya, A. Hubalewska-Dydejczyk, P. Laurberg, R. Negro, F. Vermiglio, K. G. Poppe. (2011) Treatment and Screening of Hypothyroidism in Pregnancy: Results of a European Survey. European Journal of Endocrinology
CrossRef12
Alex Stagnaro-Green, Marcos Abalovich, Erik Alexander, Fereidoun Azizi, Jorge Mestman, Roberto Negro, Angelita Nixon, Elizabeth N. Pearce, Offie P. Soldin, Scott Sullivan, Wilmar Wiersinga. (2011) Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 21:10, 1081-1125
CrossRef13
D. Führer. (2011) Schilddrüsenerkrankungen und Schwangerschaft. Der Internist 52:10, 1158-1166
CrossRef14
Melissa A. Parisi, Catherine Y. Spong, Anne Zajicek, Alan E. Guttmacher. (2011) We don't know what we don't study: The case for research on medication effects in pregnancy. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 157:3, 247-250
CrossRef15
NEIL K VANES, JOHN H LAZARUS, SHIAO-Y CHAN. (2011) THYROID FUNCTION IN PREGNANCY: MATERNAL AND FETAL OUTCOMES WITH HYPOTHYROIDISM AND SUBCLINICAL THYROID DYSFUNCTION. Fetal and Maternal Medicine Review 22:03, 169-187
CrossRef16
Kris Poppe, David Unuane, Miguel D’Haeseleer, Herman Tournaye, Johan Schiettecatte, Patrick Haentjens, Brigitte Velkeniers. (2011) Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome. Fertility and Sterility 96:1, 241-245
CrossRef17
Fabrice Herin, Elisa Boutet-Robinet, Aude Levant, Sylvain Dulaurent, Mimoza Manika, Florence Galatry-Bouju, Philippe Caron, Jean-Marc Soulat. (2011) Thyroid Function Tests in Persons with Occupational Exposure to Fipronil. Thyroid 21:7, 701-706
CrossRef18
(2011) Embarazo y puerperio. FMC - Formación Médica Continuada en Atención Primaria 18, 9-52
CrossRef19
Samuel A. Pauli, Caleb B. Kallen. 2011. Endocrine Disorders and Infertility. , 90-101.
CrossRef20
Syed Ali Imran, Murali Rajaraman. (2011) Management of Differentiated Thyroid Cancer in Pregnancy. Journal of Thyroid Research 2011, 1-5
CrossRef21
Ghalia Ashoor, Nerea Maiz, Howard Cuckle, Firas Jawdat, Kypros H Nicolaides. (2011) Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18. Prenatal Diagnosis 31:1, 33-37
CrossRef22
Marcos Abalovich, Graciela Alcaraz, Jessica Kleiman-Rubinsztein, María Magdalena Pavlove, Cecilia Cornelio, Oscar Levalle, Silvia Gutierrez. (2010) The Relationship of Preconception Thyrotropin Levels to Requirements for Increasing the Levothyroxine Dose During Pregnancy in Women with Primary Hypothyroidism. Thyroid 20:10, 1175-1178
CrossRef23
Shiao Y. Chan. (2010) Thyroid gland: Early adjustment of levothyroxine treatment in pregnancy. Nature Reviews Endocrinology 6:10, 537-538
CrossRef24
Dania Hirsch, Sigal Levy, Gloria Tsvetov, Ruth Weinstein, Avner Lifshitz, Joelle Singer, Ilana Shraga-Slutzky, Simona Grozinski-Glasberg, Ilan Shimon, Carlos Benbassat. (2010) Impact of Pregnancy on Outcome and Prognosis of Survivors of Papillary Thyroid Cancer. Thyroid 20:10, 1179-1185
CrossRef25
Martin N. Montoro. 2010. Thyroid Disease in Pregnancy: Hypothyroidism. , 102-105.
CrossRef26
Brian M. Casey. 2010. Hyperthyroidism and Hypothyroidism in Pregnancy. , 237-242.
CrossRef27
Erin Keely, Brian M. Casey. 2010. Thyroid Disease in Pregnancy. , 322-334.
CrossRef28
Antonio De Vivo, Alfredo Mancuso, Annamaria Giacobbe, Mariacarla Moleti, Laura Maggio Savasta, Rosanna De Dominici, Antonio Maria Priolo, Francesco Vermiglio. (2010) Thyroid Function in Women Found to Have Early Pregnancy Loss. Thyroid 20:6, 633-637
CrossRef29
Diana L. Fitzpatrick, Michelle A. Russell. (2010) Diagnosis and Management of Thyroid Disease in Pregnancy. Obstetrics and Gynecology Clinics of North America 37:2, 173-193
CrossRef30
Talay Kudaiberdiev, Gulzad Imanalieva, Gulbarchin Usupbaeva, Rahat Kalieva, Elmira Tukusheva. (2010) Gross pericardial effusion with tamponade in 2nd trimester of pregnancy. Central European Journal of Medicine 5:3, 369-371
CrossRef31
Megan R. Haymart, Max A. Cayo, Herbert Chen. (2010) Thyroid Hormone Replacement in Women of Reproductive Age: Is Surgeon Knowledge Related to Operative Volume?. Thyroid 20:6, 627-631
CrossRef32
Megan Rist Haymart. (2010) The Role of Clinical Guidelines in Patient Care: Thyroid Hormone Replacement in Women of Reproductive Age. Thyroid 20:3, 301-307
CrossRef33
Angela M. Leung, Elizabeth N. Pearce, Lewis E. Braverman. (2010) Perchlorate, iodine and the thyroid. Best Practice & Research Clinical Endocrinology & Metabolism 24:1, 133-141
CrossRef34
Eui Young Kim, Won Gu Kim, Tae Yong Kim, Jong Ho Yoon, Suck Joon Hong, Young Kee Shong, Won Bae Kim. (2010) Factors Influencing Peripheral Conversion of Thyroxine to Tri-Iodothyronine in Athyreotic Individuals during Levothyroxine Replacement. Endocrinology and Metabolism 25:2, 119
CrossRef35
Roland Gärtner. (2009) Thyroid diseases in pregnancy. Current Opinion in Obstetrics and Gynecology 21:6, 501-507
CrossRef36
Rundsarah Tahboub, Baha M. Arafah. (2009) Sex steroids and the thyroid. Best Practice & Research Clinical Endocrinology & Metabolism 23:6, 769-780
CrossRef37
Geeta Chadha, Mamta Goel. (2009) Hypothyroidism in Pregnancy. Apollo Medicine 6:4, 322-326
CrossRef38
B. Harbeck, H. Lehnert, H. Mönig. (2009) Schilddrüsenentzündungen in Schwangerschaft und Stillzeit. Gynäkologische Endokrinologie 7:4, 224-230
CrossRef39
Juan C. Galofre, Terry F. Davies. (2009) Autoimmune Thyroid Disease in Pregnancy: A Review. Journal of Women's Health 18:11, 1847-1856
CrossRef40
Erik K. Alexander. (2009) Thyroid function: The complexity of maternal hypothyroidism during pregnancy. Nature Reviews Endocrinology 5:9, 480-481
CrossRef41
Anita K. Ying, Winston Huh, Sarah Bottomley, Douglas B. Evans, Steven G. Waguespack. (2009) Thyroid Cancer in Young Adults. Seminars in Oncology 36:3, 258-274
CrossRef42
Stefan Karger, Dagmar Führer-Sakel. (2009) Schilddrüsenerkrankungen und Schwangerschaft. Medizinische Klinik 104:6, 450-456
CrossRef43
Uberta Verga, Silvia Bergamaschi, Donatella Cortelazzi, Stefania Ronzoni, Anna Maria Marconi, Paolo Beck-Peccoz. (2009) Adjustment of L-T 4 substitutive therapy in pregnant women with subclinical, overt or post-ablative hypothyroidism. Clinical Endocrinology 70:5, 798-802
CrossRef44
John C. Morris. (2009) How do you approach the problem of TSH elevation in a patient on high-dose thyroid hormone replacement?. Clinical Endocrinology 70:5, 671-673
CrossRef45
Kenneth D. Burman. (2009) Controversies Surrounding Pregnancy, Maternal Thyroid Status, and Fetal Outcome. Thyroid 19:4, 323-326
CrossRef46
Jennifer A. Loh, Leonard Wartofsky, Jacqueline Jonklaas, Kenneth D. Burman. (2009) The Magnitude of Increased Levothyroxine Requirements in Hypothyroid Pregnant Women Depends upon the Etiology of the Hypothyroidism. Thyroid 19:3, 269-275
CrossRef47
Jim R. STOCKIGT. (2009) Obstetric implications of current Australian product information for thyroid-related medications. Australian and New Zealand Journal of Obstetrics and Gynaecology 49:1, 64-66
CrossRef48
Christin Spielhagen, Katja Bobermien, Alexander Krebs, Henri Wallaschofski. (2009) Schilddrüsendiagnostik in der Schwangerschaft. Referenzwerte und klinische Anwendung / Reference values for thyroid function tests during pregnancy. LaboratoriumsMedizin 33:1, 7-10
CrossRef49
Christin Spielhagen, Katja Bobermien, Alexander Krebs, Henri Wallaschofski. (2009) Reference values for thyroid function tests during pregnancy 1. LaboratoriumsMedizin 33:1, ---
CrossRef50
Christian De Geyter, Sabine Steimann, Beat Müller, Marius E. Kränzlin, Christian Meier. (2009) Pattern of Thyroid Function During Early Pregnancy in Women Diagnosed with Subclinical Hypothyroidism and Treated with
l -Thyroxine Is Similar to That in Euthyroid Controls. Thyroid 19:1, 53-59
CrossRef51
Linda A. Barbour. 2009. Thyroid Disease in Pregnancy. , 328-341.
CrossRef52
Stephen F. Thung, Errol R. Norwitz. 2009. Endocrine Diseases of Pregnancy. , 615-658.
CrossRef53
Alice Y. Chang, Richard J Auchus. 2009. Endocrine Disturbances Affecting Reproduction. , 561-575.
CrossRef54
A Kothari, J Girling. (2008) Hypothyroidism in pregnancy: pre-pregnancy thyroid status influences gestational thyroxine requirements. BJOG: An International Journal of Obstetrics & Gynaecology 115:13, 1704-1708
CrossRef55
Willy Visser. 2008. The patient with thyroid disease. , 89-98.
CrossRef56
Richard S Legro, Anuja Dokras. 2008. Achieving pregnancy in the anovulatory woman. , 215-222.
CrossRef57
Guy Van Vliet, Michel Polak, E Martin Ritzén. (2008) Treating fetal thyroid and adrenal disorders through the mother. Nature Clinical Practice Endocrinology & Metabolism 4:12, 675-682
CrossRef58
Joanna Girling. (2008) Thyroid disease in pregnancy. The Obstetrician & Gynaecologist 10:4, 237-243
CrossRef59
Onyebuchi E Okosieme, Helen Marx, John H Lazarus. (2008) Medical management of thyroid dysfunction in pregnancy and the postpartum. Expert Opinion on Pharmacotherapy 9:13, 2281-2293
CrossRef60
Kris Poppe, Daniel Glinoer, Herman Tournaye, Paul Devroey, Brigitte Velkeniers. (2008) Impact of the Ovarian Hyperstimulation Syndrome on Thyroid Function. Thyroid 18:7, 801-802
CrossRef61
Kris Poppe, Brigitte Velkeniers, Daniel Glinoer. (2008) The role of thyroid autoimmunity in fertility and pregnancy. Nature Clinical Practice Endocrinology & Metabolism 4:7, 394-405
CrossRef62
G. R. Williams. (2008) Neurodevelopmental and Neurophysiological Actions of Thyroid Hormone. Journal of Neuroendocrinology 20:6, 784-794
CrossRef63
R. Gärtner, M. Reincke. (2008) Substitution von Schilddrüsenhormonen. Der Internist 49:5, 538-544
CrossRef64
Roberto Negro. (2008) Thyroid insufficiency during pregnancy: complications and implications for screening. Expert Review of Endocrinology & Metabolism 3:2, 137-146
CrossRef65
Christina Cotzias, Sarah-Jane Wong, Erica Taylor, Paul Seed, Joanna Girling. (2008) A study to establish gestation-specific reference intervals for thyroid function tests in normal singleton pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology 137:1, 61-66
CrossRef66
Jorge H. Mestman. 2008. Thyroid diseases in pregnancy. , 343-351.
CrossRef67
Frank Nawroth, Michael Ludwig. (2008) What can we expect if we measure hormones in eumenorrhoeic infertile patients?. Reproductive BioMedicine Online 16:5, 621-626
CrossRef68
P Laurberg, S Andersen, R I Bjarnadóttir, A Carlé, AB Hreidarsson, N Knudsen, L Ovesen, IB Pedersen, LB Rasmussen. (2007) Evaluating iodine deficiency in pregnant women and young infants—complex physiology with a risk of misinterpretation. Public Health Nutrition 10:12A,
CrossRef69
Gabriella Morreale de Escobar, María Jesús Obregón, Francisco Escobar del Rey. (2007) Iodine deficiency and brain development in the first half of pregnancy. Public Health Nutrition 10:12A,
CrossRef70
Yutaka Aoki, Ruth M. Belin, Robert Clickner, Rebecca Jeffries, Linda Phillips, Kathryn R. Mahaffey. (2007) Serum TSH and Total T 4 in the United States Population and Their Association With Participant Characteristics: National Health and Nutrition Examination Survey (NHANES 1999–2002). Thyroid 17:12, 1211-1223
CrossRef71
Yasuyuki Arai, Koichiro Nabe, Hiroki Ikeda, Sachiko Honjo, Yoshiharu Wada, Yoshiyuki Hamamoto, Kazuhiro Nomura, Tomokazu Aoki, Toshiaki Sano, Hiroyuki Koshiyama. (2007) A case of lymphocytic panhypophysitis (LPH) during pregnancy. Endocrine 32:1, 117-121
CrossRef72
(2007) Pregnancy Guidelines. Thyroid 17:11, 1159-1167
CrossRef73
Mumtaz Rashid, Mohammed H. Rashid. (2007) Obstetric Management of Thyroid Disease. Obstetrical & Gynecological Survey 62:10, 680-688
CrossRef74
Madhuri Devdhar, Yasser H. Ousman, Kenneth D. Burman. (2007) Hypothyroidism. Endocrinology & Metabolism Clinics of North America 36:3, 595-615
CrossRef75
Allen W Root. (2007) Endocrinology and metabolism 2007. Current Opinion in Pediatrics 19:4, 455-457
CrossRef76
Marie D. Rinaldi, Alex S. Stagnaro-Green. (2007) Thyroid Disease and Pregnancy: Degrees of Knowledge. Thyroid 17:8, 747-753
CrossRef77
Lynn B. Davis, Ruth B. Lathi, Michael H. Dahan. (2007) The Effect of Infertility Medication on Thyroid Function in Hypothyroid Women Who Conceive. Thyroid 17:8, 773-777
CrossRef78
Giampaolo Papi, Ettore degli Uberti, Corrado Betterle, Cesare Carani, Elizabeth N Pearce, Lewis E Braverman, Elio Roti. (2007) Subclinical hypothyroidism. Current Opinion in Endocrinology, Diabetes and Obesity 14:3, 197-208
CrossRef79
Rebecca Leboeuf, Lana E. Emerick, Andrew J. Martorella, R. Michael Tuttle. (2007) Impact of Pregnancy on Serum Thyroglobulin and Detection of Recurrent Disease Shortly After Delivery in Thyroid Cancer Survivors. Thyroid 17:6, 543-547
CrossRef80
G. Ducarme, J. Bertherat, E. Vuillard, M. Polak, J. Guibourdenche, D. Luton. (2007) Pathologies thyroïdiennes et grossesse. La Revue de Médecine Interne 28:5, 314-321
CrossRef81
Kris Poppe, Brigitte Velkeniers, Daniel Glinoer. (2007) Thyroid disease and female reproduction. Clinical Endocrinology 66:3, 309-321
CrossRef82
Brian M. Casey, Kenneth J. Leveno. (2006) Thyroid Disease in Pregnancy. Obstetrics & Gynecology 108:5, 1283-1292
CrossRef83
Lívia P. Lima, Inês A. Barros, Patrícia C. Lisbôa, Renata L. Araújo, Alba C.M. Silva, Doris Rosenthal, Andrea C.F. Ferreira, Denise P. Carvalho. (2006) Estrogen effects on thyroid iodide uptake and thyroperoxidase activity in normal and ovariectomized rats. Steroids 71:8, 653-659
CrossRef84
Leonard Wartofsky, Douglas Van Nostrand, Kenneth D. Burman. (2006) Overt and ???Subclinical??? Hypothyroidism in Women. Obstetrical & Gynecological Survey 61:8, 535-542
CrossRef85
Thien-Giang Bach-Huynh, Jacqueline Jonklaas. (2006) Thyroid Medications During Pregnancy. Therapeutic Drug Monitoring 28:3, 431-441
CrossRef86
(2006) Discussion. American Journal of Obstetrics and Gynecology 194:6, 1674-1675
CrossRef87
Valerie L. Baker, Heather M. Rone, David J. Pasta, H. Preston Nelson, Marina Gvakharia, G. David Adamson. (2006) Correlation of thyroid stimulating hormone (TSH) level with pregnancy outcome in women undergoing in vitro fertilization. American Journal of Obstetrics and Gynecology 194:6, 1668-1674
CrossRef88
Mario Rotondi, Sara Precerutti, Luca Chiovato. (2006) Maternal hypothyroidism in early gestation: possible preventive strategies. Clinical Endocrinology 64:5, 599-601
CrossRef89
Centanni, Marco, Gargano, Lucilla, Canettieri, Gianluca, Viceconti, Nicola, Franchi, Antonella, Fave, Gianfranco Delle, Annibale, Bruno, . (2006) Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis. New England Journal of Medicine 354:17, 1787-1795
Full Text90
Edmund F La Gamma, Aleid G van Wassenaer, Sergio G Golombek, Gabriella Morreale de Escobar, Joke H Kok, Jose Quero, Susana Ares, Nigel Paneth, Delbert Fisher. (2006) Neonatal Thyroxine Supplementation for Transient Hypothyroxinemia of Prematurity. Treatments in Endocrinology 5:6, 335-346
CrossRef91
Dominique Luton, Isabelle Le Gac, Michele Noel, Jean Guibourdenche, Michel Polak. (2005) Thyroid function during pregnancy in women with past Graves' disease. BJOG: An International Journal of Obstetrics and Gynaecology 112:11, 1565-1567
CrossRef92
Bernadette Biondi, Sebastiano Filetti, Martin Schlumberger. (2005) Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice Endocrinology & Metabolism 1:1, 32-40
CrossRef93
Iskandar Idris, Ramalingam Srinivasan, Andrew Simm, Renee C. Page. (2005) Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome. Clinical Endocrinology 63:5, 560-565
CrossRef94
Rui Lu, Kenneth D. Burman, Jacqueline Jonklaas. (2005) Transient Graves' Hyperthyroidism During Pregnancy in a Patient with Hashimoto's Hypothyroidism. Thyroid 15:7, 725-729
CrossRef95
Lyndal R. HARBORNE, Claire E. ALEXANDER, Andrew J. THOMSON, Denis St J. O'REILLY, Ian A. GREER. (2005) Outcomes of pregnancy complicated by thyroid disease. The Australian and New Zealand Journal of Obstetrics and Gynaecology 45:3, 239-242
CrossRef96
Terence T Lao. (2005) Thyroid disorders in pregnancy. Current Opinion in Obstetrics and Gynecology 17:2, 123-127
CrossRef97
Mark F. Prummel, Wilmar M. Wiersinga. (2005) Thyroid peroxidase autoantibodies in euthyroid subjects. Best Practice & Research Clinical Endocrinology & Metabolism 19:1, 1-15
CrossRef98
William L. Green. (2005) New questions regarding bioequivalence of levothyroxine preparations: A Clinician's response. The AAPS Journal 7:1, E54-E58
CrossRef99
Joanne Rovet. (2005) Congenital hypothyroidism: treatment and outcome. Current Opinion in Endocrinology & Diabetes 12:1, 42-52
CrossRef100
M. Ludwig, H. M. Schulte. (2005) Schilddrüse bei unerfülltem Kinderwunsch, in Schwangerschaft und Stillzeit. Gynäkologische Endokrinologie 3:1, 45-54
CrossRef101
Shiao Y Chan, Jayne A Franklyn, Mark D Kilby. (2005) Maternal thyroid hormones and fetal brain development. Current Opinion in Endocrinology & Diabetes 12:1, 23-30
CrossRef102
A. C. M. Vingerhoeds. (2005) Toegenomen thyroxinebehoefte tijdens de zwangerschap. Medisch-Farmaceutische Mededelingen 43:1, 2-3
CrossRef103
John H Lazarus. (2005) Thyroid Disorders Associated with Pregnancy. Treatments in Endocrinology 4:1, 31-41
CrossRef104
Robert C. Smallridge, Daniel Glinoer, Joseph G. Hollowell, Gregory Brent. (2005) Thyroid Function Inside and Outside of Pregnancy: What Do We Know and What Don't We Know?. Thyroid 15:1, 54-59
CrossRef105
Toft, Anthony, . (2004) Increased Levothyroxine Requirements in Pregnancy — Why, When, and How Much?. New England Journal of Medicine 351:3, 292-294
Full Text
